Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

▤ Summary

Oak Hill Bio secured $32.5 million in Series A financing to advance rugonersen, its antisense oligonucleotide therapy for Angelman syndrome. The company plans to move the program into a pivotal Phase 3 clinical study in mid-2026. The financing was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Oak Hill Bio also added Doug Fambrough, Rich Gaster, and Sandeep Kulkarni to its board of directors. The company focuses on acquiring and developing rare disease drugs that larger pharma companies have deprioritized.

$ Funding

▦ Linked Companies